


# PRODUCT INFORMATION



## BPR1J-097

Item No. 29805

**CAS Registry No.:** 1327167-19-0  
**Formal Name:** 4-(4-methyl-1-piperazinyl)-N-[5-[3-[(phenylsulfonyl)amino]phenyl]-1H-pyrazol-3-yl]-benzamide  
**MF:** C<sub>27</sub>H<sub>28</sub>N<sub>6</sub>O<sub>3</sub>S  
**FW:** 516.6  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 298 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

BPR1J-097 is supplied as a crystalline solid. A stock solution may be made by dissolving the BPR1J-097 in the solvent of choice, which should be purged with an inert gas. BPR1J-097 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of BPR1J-097 in these solvents is approximately 10 and 30 mg/ml, respectively.

BPR1J-097 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BPR1J-097 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. BPR1J-097 has a solubility of approximately 0.14 mg/ml in a 1:6 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

BPR1J-097 is an inhibitor of FMS-related tyrosine kinase 3 (FLT3; IC<sub>50</sub> = 11 nM).<sup>1</sup> It is selective for FLT3 over FLT1, KDR, Aurora A, and Aurora B kinases (IC<sub>50</sub>s = 211, 129, 340, and 876 nM, respectively). BPR1J-097 inhibits FLT3 activity and phosphorylation of STAT5 in MV4-11 acute myeloid leukemia (AML) cells containing the FLT3 activating mutant FLT3-ITD (IC<sub>50</sub>s = ~10 and 1 nM, respectively). It inhibits the growth of FLT3-dependent MOLM-13 and MV4-11 AML cells (GI<sub>50</sub>s = 21 and 46 nM, respectively) but not FLT3<sup>-/-</sup> U937 and K562 cells (GI<sub>50</sub>s = >20,000 nM for both). BPR1J-097 (25 mg/kg) inhibits tumor growth in a MOLM-13 mouse xenograft model.

### Reference

1. Lin, W.-H., Jiaang, W.-T., Chen, C.-W., *et al.* BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. *Br. J. Cancer* **106**(3), 475-481 (2012).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/15/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM